within Pharmacolibrary.Drugs.ATC.M;

model M09AX11
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.33,
    Cl             = 0.00022666666666666666,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.282,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.004166666666666667,
    Tlag           = 19.8,            
    Vdp             = 0.49,
    k12             = 48.7,
    k21             = 48.7
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M09AX11</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Palovarotene is a selective retinoic acid receptor gamma (RARγ) agonist developed for the treatment of fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder involving heterotopic ossification. As of 2023, palovarotene is approved in some regions for FOP and used under clinical investigation in others.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after oral administration of single and multiple doses.</p><h4>References</h4><ol><li><p>Dube, L, et al., &amp; Le Quan Sang, KH (2023). A Pharmacokinetic, Safety, and Tolerability Trial of Palovarotene in Healthy Japanese and Non-Japanese Participants. <i>European journal of drug metabolism and pharmacokinetics</i> 48(2) 141–150. DOI:<a href=\"https://doi.org/10.1007/s13318-023-00815-x\">10.1007/s13318-023-00815-x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36802022/\">https://pubmed.ncbi.nlm.nih.gov/36802022</a></p></li><li><p>Marino, R, et al., &amp; Le Quan Sang, KH (2023). The Pharmacokinetic Profile of Palovarotene: An Open-Label Phase I Trial Investigating the Effect of Food and Potential for Drug-Drug Interaction in Healthy Participants. <i>European journal of drug metabolism and pharmacokinetics</i> 48(6) 691–707. DOI:<a href=\"https://doi.org/10.1007/s13318-023-00856-2\">10.1007/s13318-023-00856-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37804430/\">https://pubmed.ncbi.nlm.nih.gov/37804430</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M09AX11;
